EA200800175A1 - NEW HETEROCYCLIC INHIBITORS NF-κB - Google Patents

NEW HETEROCYCLIC INHIBITORS NF-κB

Info

Publication number
EA200800175A1
EA200800175A1 EA200800175A EA200800175A EA200800175A1 EA 200800175 A1 EA200800175 A1 EA 200800175A1 EA 200800175 A EA200800175 A EA 200800175A EA 200800175 A EA200800175 A EA 200800175A EA 200800175 A1 EA200800175 A1 EA 200800175A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nrr
aryl
heterocycloalkyl
haloalkyl
hydroxyalkyl
Prior art date
Application number
EA200800175A
Other languages
Russian (ru)
Other versions
EA016300B1 (en
Inventor
Йоханн Лебан
Харальд Шмитт
Кристина Вольф
Стефано Пегораро
Андреас Вуцик
Original Assignee
4ЭсЦэ АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2005/008261 external-priority patent/WO2006032322A1/en
Application filed by 4ЭсЦэ АГ filed Critical 4ЭсЦэ АГ
Publication of EA200800175A1 publication Critical patent/EA200800175A1/en
Publication of EA016300B1 publication Critical patent/EA016300B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям общей формулы (III), или их фармацевтически приемлемым солям с кислотой или основанием, или или их фармацевтически приемлемым пролекарствам или стереоизомерам. Формула (III), где Rпредставляет собой Н, -С(O)NRR, галоген, алкил, галогеноалкил, арил, гетероарил, ОН, SH, NROR, NH, амин, алкиламин, алкокси, циклоалкил, гетероциклоалкил, гидроксиалкил или галогеноалкилокси; Rпредставляет собой Н, галоген, алкил, -C(NR)NRR, -(СН)арил, -(CH)NRR, -C(O)NRR, -N=CRR, -NRC(O)R, циклоалкил, гетероциклоалкил, галогеноалкил, гидроксиалкил, гидроксиалкиламино, алкиламино, гетероарил или арил; Rпредставляет собой галоген, алкил,-C(NR)NRR, -(СН)арил, -(CH)NRR, -C(O)NRR, -N=CRR, -NRC(O)R, циклоалкил, гетероциклоалкил, галогеноалкил, гидроксиалкил, гидроксиалкиламино, алкиламино, гетероарил или арил.The present invention relates to compounds of general formula (III), or their pharmaceutically acceptable salts with an acid or base, or or their pharmaceutically acceptable prodrugs or stereoisomers. Formula (III) where R is H, —C (O) NRR, halogen, alkyl, haloalkyl, aryl, heteroaryl, OH, SH, NROR, NH, amine, alkylamine, alkoxy, cycloalkyl, heterocycloalkyl, hydroxyalkyl or haloalkyloxy; R is H, halogen, alkyl, —C (NR) NRR, - (CH) aryl, - (CH) NRR, —C (O) NRR, —N = CRR, —NRC (O) R, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl or aryl; R is halogen, alkyl, —C (NR) NRR, - (CH) aryl, - (CH) NRR, —C (O) NRR, —N = CRR, —NRC (O) R, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl or aryl.

EA200800175A 2005-07-29 2006-03-15 NOVEL HETEROCYCLIC NF-κB INHIBITORS EA016300B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/008261 WO2006032322A1 (en) 2004-09-20 2005-07-29 NOVEL HETEROCYCLIC NF-κB INHIBITORS
PCT/EP2006/002396 WO2007016979A2 (en) 2005-07-29 2006-03-15 NOVEL HETEROCYCLIC NF-κB INHIBITORS

Publications (2)

Publication Number Publication Date
EA200800175A1 true EA200800175A1 (en) 2008-08-29
EA016300B1 EA016300B1 (en) 2012-04-30

Family

ID=36570358

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800175A EA016300B1 (en) 2005-07-29 2006-03-15 NOVEL HETEROCYCLIC NF-κB INHIBITORS

Country Status (13)

Country Link
JP (1) JP2009502816A (en)
KR (1) KR20080031038A (en)
CN (1) CN101233119A (en)
AU (1) AU2006278998A1 (en)
BR (1) BRPI0614188A2 (en)
CA (1) CA2617225A1 (en)
EA (1) EA016300B1 (en)
IL (1) IL189112A0 (en)
NO (1) NO20081056L (en)
NZ (2) NZ565470A (en)
SG (1) SG172738A1 (en)
UA (1) UA97348C2 (en)
WO (1) WO2007016979A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1797084A1 (en) * 2004-09-20 2007-06-20 4Sc Ag NOVEL HETEROCYCLIC NF-kB INHIBITORS
BRPI0709595A2 (en) * 2006-03-15 2011-07-19 4Sc Ag heterocyclic nf-kapab inhibitors
AU2008300497A1 (en) * 2007-09-19 2009-03-26 4Sc Ag Benzimidazole NF- kappab inhibitors
KR101591482B1 (en) 2008-05-28 2016-02-03 레베라겐 바이오파마 인코포레이티드 - non-hormonal steroid modulators of nf-b for treatment of disease
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
PT2959900T (en) 2008-06-16 2017-06-22 Univ Tennessee Res Found Compound for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
CN102883607B (en) 2010-03-01 2015-07-22 Gtx公司 Compounds for treatment of cancer
CA2855756A1 (en) * 2011-11-29 2013-06-06 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of nf-kb for treatment of disease
AU2014283378B2 (en) * 2013-06-18 2018-09-27 4Sc Ag 2,3-dihydrobenzofuran-5-yl compounds as DYRK kinase inhibitors
NZ722487A (en) * 2014-01-29 2022-04-29 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
WO2024145662A1 (en) * 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263508B (en) * 1991-02-12 1995-11-21 Pfizer
CN1063442C (en) * 1995-05-18 2001-03-21 泽里新药工业株式会社 Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds
JPH0987282A (en) * 1995-09-21 1997-03-31 Kyowa Hakko Kogyo Co Ltd Thiazole derivative
AU6966696A (en) * 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
DE19817459A1 (en) * 1998-04-20 1999-10-21 Basf Ag New heterocyclic amide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
US6506747B1 (en) * 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
DE19858593A1 (en) * 1998-12-18 2000-06-21 Merck Patent Gmbh (2-Phenyl-4-(phenylsulfonyl)-oxazol-5-yl)-amine therapeutic agents having 5-HT6 receptor affinity, useful for treating CNS disorders such as psychosis, schizophrenia, depression or Alzheimer's disease
ATE318809T1 (en) * 1999-11-05 2006-03-15 Sod Conseils Rech Applic HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICATIONS
AU2002248432A1 (en) * 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
WO2003027096A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
GB0130868D0 (en) * 2001-12-24 2002-02-06 Univ Strathclyde New compounds
AU2003205570A1 (en) * 2002-01-10 2003-07-24 Boehringer Ingelheim Pharma Gmbh And Co. Kg Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs
SI1549652T1 (en) * 2002-09-30 2009-04-30 Bayer Healthcare Ag Fused azole-pyrimidine derivatives
GB0230162D0 (en) * 2002-12-24 2003-02-05 Metris Therapeutics Ltd Compounds useful in inhibiting angiogenesis
FR2856685B1 (en) * 2003-06-25 2005-09-23 Merck Sante Sas THIAZOLYLPIPERIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
US20050209284A1 (en) * 2004-02-12 2005-09-22 Boehringer Ingelheim Pharmaceuticals, Inc. Tec kinase inhibitors
WO2005090319A1 (en) * 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
EP1797084A1 (en) * 2004-09-20 2007-06-20 4Sc Ag NOVEL HETEROCYCLIC NF-kB INHIBITORS

Also Published As

Publication number Publication date
WO2007016979A2 (en) 2007-02-15
JP2009502816A (en) 2009-01-29
EA016300B1 (en) 2012-04-30
WO2007016979A3 (en) 2007-08-02
NO20081056L (en) 2008-02-28
KR20080031038A (en) 2008-04-07
NZ565470A (en) 2010-11-26
BRPI0614188A2 (en) 2011-03-15
IL189112A0 (en) 2008-08-07
SG172738A1 (en) 2011-07-28
UA97348C2 (en) 2012-02-10
NZ588971A (en) 2012-06-29
AU2006278998A1 (en) 2007-02-15
CA2617225A1 (en) 2007-02-15
CN101233119A (en) 2008-07-30

Similar Documents

Publication Publication Date Title
EA200800175A1 (en) NEW HETEROCYCLIC INHIBITORS NF-κB
ES2528451T3 (en) Sphingosine kinase inhibitors
EA200900934A1 (en) NEW HETEROCYCLIC INHIBITORS NF-κB
EA200700441A1 (en) NEW HETEROCYCLIC INHIBITORS NF-κB
CY1112914T1 (en) Substituted Indolyl Alkyl Amine Derivatives as New Suspensions of Hastonine Disinfectants
ECSP12012212A (en) ARYLETINYL DERIVATIVES
NZ627036A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
RU2015121431A (en) SUBSTITUTED INDOL-5-OLA DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
EA201591000A1 (en) Pyrrolobenzodiazepine
EA201170096A1 (en) SUBSTITUTED PYRIMIDON DERIVATIVES
EA201490535A1 (en) Pyrrolbenzodiazepine
HRP20130851T1 (en) Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
EA200970172A1 (en) PRINCIPLE OF CONNECTION AMIDA BOROIC ACID
EA200802389A1 (en) ASYRIDINYLEPOTILON COMPOUNDS
CO6160296A2 (en) BENZOAZEPIN-OXI-ACETIC ACID DERIVATIVES AS RECEPTOR AGONISTS ACTIVATED BY DELTA PEROXISONE PROLIFERATOR USED TO INCREASE HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL-CHOLESTEROL REDUCE LIPOPROTEIN-LOW DENSITY-COLESTEROL
AR047817A1 (en) DERIVATIVES OF ARIL- AND HETEROARILPIPERIDINCARBOXILATOS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
AR086590A1 (en) CYCLHEXANONE AND HERBICIDE COMPOUNDS THAT UNDERSTAND THEM
EA200801838A1 (en) NEW HETEROCYCLIC INHIBITORS NF-kB
UY29023A1 (en) PROCEDURE FOR PREPARATION OF DERIVATIVES N- PIPERIDINO - 1, 5 - DIFENILPIRAZOL - 3 - CARBOXAMIDA.-
RU2012116525A (en) METHODS FOR PRODUCING PERIMIDINE DERIVATIVES USED AS PROTEINKINASE INHIBITORS
AR082111A1 (en) FUROPIRIDINES OR CONDENSED TENOPIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM USEFUL TO TREAT PSYCHOTIC AND CENTRAL NERVOUS SYSTEM DISORDERS, AND THE SAME PREPARATION METHOD
EA201000881A1 (en) Pyridylmethyl-sulfonamide compounds
AR075951A1 (en) DIHIDROPIRIDIN SULFONAMIDS AND DIHIDROPIRIDIN SULFAMIDS AS MEK INHIBITORS
PE20020524A1 (en) 7-OXO-PYRIDOPYRIMIDINES AS KINASE INHIBITORS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU